This Wednesday showed a session of vivid trading activity for Fibrocell Sciences Inc.(OTC:FCSC), and a positive movement of the stock price. Yet, this is nothing, compared to what might be coming during the same time next week. The question is – what would the direction be? 
After reaching the $1 in April, FCSC has been holding it, with decent levels of trading activity over the last two months. Yesterday session was no exception with 840k shares exchanging hands, the session closing at $1.14 per share. Now, there are no recent press releases from this company. Nothing in June so far, at least. Yet, an interesting article makes its way to the public at the moment.Â
An article, focusing on the date June 22th. A date, on which Fibrocell could expect a response from the FDA for one of its products. To be more precise – one product which if approved would be the first that Fibrocell would market. A proper catalyst, indeed. Yet, the stock would benefit if approval is the answer to come.
There are other facts that should not go unnoticed while focusing on the above Wednesday to come. Facts coming from the SEC filing. The 10-Q for the first 3 months of 2011 includes the following:
- As of May 9, 2011 the Company had cash and cash equivalents of approximately $2.0 million;
- The company’s current monthly cash run-rate is approximately $1.0 million;
- $17 million in net loss for Q1,2011; [BANNER]
Not the most optimistic numbers out there, for sure. In terms, this means Fibrocell would require additional funding for its operations. A task that would be a lot easier if there was an FDA approval for the product in question mentioned above. Ultimately, this would determine the short-term direction that this stock would take.
